(Q36213129)

12 August 2017

1 reference

title

Treatment of menopausal symptoms: what shall we do now? (English)

1 reference

12 August 2017

Martha Hickey

1

0 references

Susan R. Davis

object named as

Susan R Davis

series ordinal

2

0 references

author name string

David W Sturdee

series ordinal

3

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

366

1 reference

12 August 2017

issue

9483

1 reference

12 August 2017

page(s)

409-421

1 reference

Hot flashes: epidemiology and physiology

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Physiological aspects of menopausal hot flush

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Physiology of hot flashes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Pathophysiology and treatment of hot flashes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

1 reference

7 January 2021

Markedly elevated levels of estrone sulfate after long-term oral, but not transdermal, administration of estradiol in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Serum Estradiol-Binding Profiles in Postmenopausal Women Undergoing Three Common Estrogen Replacement Therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Transdermal 17 beta-estradiol combined with oral progestogen increases plasma levels of insulin-like growth factor-I in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Bioidentical hormone therapy: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

The role of local estrogen biosynthesis in males and females

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

The clinical platform for the 17beta-estradiol vaginal releasing ring

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Postmenopausal hormone therapy and risk of developing urinary incontinence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Comparative study: Replens versus local estrogen in menopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Effect of oral medroxyprogesterone acetate on menopausal symptoms in patients with endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

A randomized double-blind cross-over trial into the effect of norethisterone on climacteric symptoms and biochemical profiles

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

The role of megestrol acetate as an alternative to conventional hormone replacement therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Differential effects of progestins on hemostasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

A population-based study of depressed mood in middle-aged, Australian-born women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Diagnosis of osteoporosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

The effect of postmenopausal estrogen therapy on bone density in elderly women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Postmenopausal hormone use and risk for colorectal cancer and adenoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Breast cancer and hormone-replacement therapy: the Million Women Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Hormones and mammographic breast density

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Impact of use of hormone replacement therapy on false positive recall in the NHS breast screening programme: results from the Million Women Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Guidelines for hormone treatment of women in the menopausal transition and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of The North American Menopause Society

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Menopause after breast cancer: a survey on breast cancer survivors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Hot flashes in breast cancer survivors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

The epidemiology of endometrial cancer in young women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Alternative analytic methods for case-control studies of estrogens and endometrial cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Endometrial cancer and estrogen use. Report of a large case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Risk of Endometrial Cancer Following Estrogen Replacement With and Without Progestins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994-1997

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Intrauterine application of progestins in hormone replacement therapy: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

The acceptability of a small intrauterine progestogen-releasing system for continuous combined hormone therapy in early postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Endometrial cancer and hormone-replacement therapy in the Million Women Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

A comparative review of the risks and benefits of hormone replacement therapy regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Estrogen plus progestin and risk of venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Postmenopausal hormone replacement therapy: scientific review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Hormone replacement therapy and associated risk of stroke in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Hormone therapy to prevent disease and prolong life in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Evidence from randomised trials on the long-term effects of hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

A clinical trial of estrogen-replacement therapy after ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Estrogen plus progestin and the risk of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

The influence of hormone replacement therapy on the aging-related change in cognitive performance. Analysis based on a Danish cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Hormone replacement therapy and reduced cognitive decline in older women: the Cache County Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Hormone replacement therapy and other potential treatments for dementias

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Predictors of difficulty when discontinuing postmenopausal hormone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

After the Women's Health Initiative: Postmenopausal women's experiences with discontinuing estrogen replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Long-term effects of tibolone on the endometrium as assessed by bleeding episodes, transvaginal scan and endometrial biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

A 2-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Tibolone actions on normal and breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Effect of tibolone on breast symptoms resulting from postmenopausal hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Transdermal testosterone treatment in women with impaired sexual function after oophorectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Phytoestrogens: pharmacological and therapeutic perspectives.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Effects of a standardized soy extract on hot flushes: a multicenter, double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Isoflavones from red clover (Promensil) significantly reduce menopausal hot flush symptoms compared with placebo.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Effects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Phytoestrogens for treatment of menopausal symptoms: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Red-clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial [ISRCTN42940165]

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Prospective evaluation of vitamin E for hot flashes in breast cancer survivors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Cimicifuga racemosa: a systematic review of its clinical efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

A comparison of acupuncture and oral estradiol treatment of vasomotor symptoms in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

The effects of relaxation response training on menopausal symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Vasomotor symptoms and quality of life in previously sedentary postmenopausal women randomised to physical activity or estrogen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Effect of a yearlong, moderate-intensity exercise intervention on the occurrence and severity of menopause symptoms in postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

A double blind study to evaluate the effect of methyldopa on menopausal vasomotor flushes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Veralipride: alternative antidopaminergic treatment for menopausal symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Transdermal clonidine for ameliorating tamoxifen-induced hot flashes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Phase III evaluation of fluoxetine for treatment of hot flashes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Systematic review of the epidemiologic and trial evidence of an association between antidepressant medication and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

KEEPS: The Kronos Early Estrogen Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966519-1

7 January 2021

10.1016/S0140-6736(05)66519-1

Identifiers

DOI

1 reference

12 August 2017

1 reference